Will Adagio's COVID Antibody Therapy Be Too Late to the Party?
4/12 13:52
Adagio Therapeutics (NASDAQ: ADGI) plans to file for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration for its COVID-19 antibody therapy in the second quarter of 2022. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Ke...